Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC says FDA delays decision on Vascepa trial design-Reuters


Wednesday, 15 Jan 2014 05:55pm EST 

Amarin Corporation PLC:Says U.S. health regulators delayed their decision to reconsider a rescinded agreement that could support a marketing application for an expanded use of the company's blood fat-lowering drug-Reuters.Says the U.S. Food and Drug Administration had in October revoked a Special Protocol Assessment (SPA) agreement covering a large late-stage trial of the drug, Vascepa.Says following an appeal from Amarin, the regulator said it would determine by Jan 15 whether it would reconsider that decision. 

Company Quote

1.58
-0.02 -1.25%
17 Apr 2014